RM-02

RM-02 is a pharmaceutical product initially developed by Azurity Pharmaceuticals as part of its ready-to-use and/or oral liquid portfolio, but publicly available information does not disclose its exact active ingredient, formulation, indication, or mechanism of action. Limited pipeline references indicate that RM-02 is an unfinished or pending development candidate aimed at U.S. FDA approval in partnership efforts, without clear evidence of clinical trial initiation, defined target, or therapeutic area. As such, RM-02 should be regarded as an early-stage or shelved Azurity development program with undisclosed pharmacology and clinical profile.